Accent Therapeutics

RNA-modifying protein inhibitors

3 additional undisclosed programs RD/Clin0 multiple cancers; undisclosed programs RD undisclosed

Accent Therapeutics is pioneering the field of epitranscriptomics to develop precision cancer therapies. Epitranscriptomics refers to a collection of RNA-modifying proteins (RMPs) that control many aspects of RNA biology and are critical drivers of specific cancers. Accent is using this insight to target RMPs with potent drug molecules to create precision cancer medicines. To date, few inhibitors of RMPs have been reported. Accent is using cutting-edge approaches with a robust chemical biology platform to identify and prioritize the most critical RMP targets and small molecules with favorable pharmacological properties, oral bioavailability and efficacy. Accent’s multi-parametric approach to lead optimization will position them to create clinic-ready molecules.